BLASUBCUTANEOUSINJECTABLE4 Generics Approved
Approved
Jun 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
4/8 — Partial
NOVOLOG (water injection) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2000.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NovoLog is a rapid-acting insulin analog administered via subcutaneous injection, approved by the FDA on June 7, 2000. It is indicated for the treatment of diabetes mellitus and works by mimicking the body's natural insulin response to control blood glucose levels. As a rapid-acting insulin, NovoLog is typically used in combination with longer-acting basal insulins or oral antidiabetic agents and serves as a mealtime insulin therapy in the insulin analog treatment landscape.
$0.5BPart D
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®
Started Jul 2024
54 enrolled
Healthy Participants
Investigation of the Analgesic Effects of Intradermal and Subdermal Sterile Water Injection on Active Labor Pain
Started Jan 2024
Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
Started Dec 2020
137 enrolled
Type 2 Diabetes Treated With Insulin
Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Started Mar 2019
210 enrolled
Type 1 Diabetes Mellitus
Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients
Started May 2018
45 enrolled
Type 1 Diabetes Mellitus
Worked on NOVOLOG at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.